Login
$IMNM
$17.69 +$0.08 (0.45%) After hours

Company Executives

Officer Age In this role Source
Clay Siegall Also a director
President, Chief Executive Officer and Chairman of the Board
65 Not stated
Max Rosett
Chief Financial Officer
36 Since 2024
2 years
Jack Higgins
Chief Scientific Officer
47 Since 2023
3 years
Kinney Horn
Chief Business Officer
51 Since 2024
2 years
Robert Lechleider
Chief Medical Officer
65 Since 2023
3 years
Sandra Stoneman
Chief Legal Officer and General Counsel
53 Since 2020
6 years
Philip Tsai
Chief Technical Officer
58 Since 2024
2 years

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
3.6 years
from year joined
CEO also chairs the board
Yes
Clay Siegall, Ph.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Clay Siegall, Ph.D.
65 2023
3 years
Not stated None stated Shattuck Labs, Inc. (Nasdaq: STTK) Paid as CEO
Isaac Barchas
58 2023
3 years
Independent
Nominating and Corporate Governance · Chair
None stated $210,000
James Boylan
59 2023
3 years
Independent
Compensation · Chair
Compass Therapeutics, Inc. (NASDAQ: CMPX) $190,000
Philip Wagenheim
55 2017
9 years
Independent None stated Swarmer Inc. (NASDAQ: SWMR) $175,000
Sandra Swain, M.D.
72 2024
2 years
Independent
Audit Committee
None stated $182,500
Carol Schafer
62 2024
2 years
Independent
Audit · Chair
Insmed Incorporated (NASDAQ: INSM), Kura Oncology, Inc. (NASDAQ: KURA) $195,000
Jean-Jacques Bienaimé
72 2023
3 years
Independent
Audit Compensation
Incyte Corporation (NASDAQ: INCY) $187,500

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 24, 2026
Clay Siegall, Ph.D.
President, CEO and Chairman of the Board
$1.0 million

Purchased 46,511 shares of common stock in the December 2025 underwritten public offering

Clay Siegall, Ph.D.
President, CEO and Chairman of the Board
$1.2 million

Purchased 150,000 shares of common stock in the January 2025 underwritten public offering

Immunome Aggregator, L.P.
Former 5% Stockholder
$10.0 million

Purchased 1,290,322 shares of common stock in the January 2025 underwritten public offering

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support